BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 2, 2010
View Archived Issues
Daiichi Sankyo reports third quarter 2009 reults
Read More
Kyowa Hakko Kirin reports third quarter 2009 results
Read More
Promising data disclosed on TNFerade for esophageal cancer
Read More
Phase II data show everolimus monotherapy to be safe and active in metastatic gastric cancer
Read More
First phase I trial of KRN-330 supports safety and tolerability in advanced CRC
Read More
Abbott presents novel analgesic agents
Read More
Vyvanse available in Canada for ADHD
Read More
Biomolecular Pharma presents antiviral agents for treatment of neural measles infection
Read More
Pfizer claims CRF1 receptor antagonists for treatment of female sexual disorders
Read More
Albany Molecular Research describes 5-HT3 receptor modulators for IBS therapy
Read More
Combination of pasireotide and everolimus feasible for neuroendocrine tumors
Read More
Wyeth identifies mGlu5 receptor antagonists as anxiolytics
Read More
Concert Pharmaceuticals claims novel HIV protease inhibitors
Read More
Ligand acquires Metabasis
Read More
Rilotumumab dose selected for randomized evaluation with panitumumab in mCRC
Read More
Zelos Therapeutics initiates dosing in phase I nasal spray teriparatide trial
Read More
Idera initiates phase I IMO-3100 trial for autoimmune disease indications
Read More
FDA expands use of GlaxoSmithKline's Tykerb in breast cancer
Read More
Stem Cell receives No Objection Letter from Health Canada for phase IIa trial
Read More
Allon initiates trial to expand safety profile for davunetide
Read More
Starpharma and Lilly sign new drug delivery collaboration
Read More
QuantRx Biomedical to acquire NuRx
Read More
FDA approves once-a-day Lamictal XR as add-on epilepsy therapy
Read More
Algeta initiates treatment in phase II clinical trial of Alpharadin in breast cancer
Read More
Leo Pharma reports results from phase III study of PEP-005 for treatment of AK lesions
Read More